ProCE Banner Activity

Metastatic Breast Cancer: Patient-Provider Communication Checklist

PDF

Patient-provider communication checklist with key facts about metastatic breast cancer, questions to ask your doctor, and available resources to cover the cost of care and other transportation expenses, and available clinical trials.

Released: October 19, 2023

Share

Faculty

Joyce O'Shaughnessy

Joyce O'Shaughnessy, MD

Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Chair, Breast Disease Committee
Texas Oncology
Sarah Cannon Research Institute
Dallas, Texas

Provided by

Provided by Clinical Care Options, LLC in partnership with Breastcancer.org.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc, Gilead Sciences, Inc., Lilly, Merck Sharp & Dohme Corp., and Novartis Pharmaceuticals Corporation.

AstraZeneca

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

Lilly

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Partners

Breastcancer.org

ProCE Banner

Faculty Disclosure

Primary Author

Joyce O'Shaughnessy, MD

Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Chair, Breast Disease Committee
Texas Oncology
Sarah Cannon Research Institute
Dallas, Texas

Joyce O'Shaughnessy, MD: consultant/advisor: AbbVie Inc., Agendia, Aptitude Health, AstraZeneca, Bayer, Bristol Myers Squibb, Caris, Carrick Therapeutics, Celgene Corporation, Daiichi Sankyo, Eisai, Exact Sciences, Fishawack Health, G1 Therapeutics, GlaxoSmithKline, Genentech, Gilead Sciences, Immunomedics, Incyte Corporation, Lilly, Loxo Oncology, Merck, Novartis, Ontada, Pfizer, Pharmacyclics, Pierre Fabre Pharmaceuticals, Puma Biotechnology, Prime Oncology, Roche, Samsung Bioepis, Sanofi, Seagen, Stemline Therapeutics, Theralink, Synthon, Veru.